Cue Biopharma (CUE)

Name: Cue Biopharma (CUE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Cue Biopharma (CUE)

Stock Card

$27.88

$-0.28 (-0.99%)

As on 28-Aug-2026 16:00EDT

Market cap

$203 Mln

Revenue (TTM)

$38 Mln

P/E Ratio

P/B Ratio

88.6

Div. Yield

0 %

Cue Biopharma (CUE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 26.85 High: 29.75

52 Week Range

Low: 4.97 High: 45.50

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-16 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.8
Debt to Equity

0
Book Value

$0.4
EPS

$-27
Face value

--
Shares outstanding

7,264,414

9 Years Aggregate

CFO

$-230.12 Mln

EBITDA

$-290.49 Mln

Net Profit

$-300.97 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Cue Biopharma (CUE)	204.3	-14.4	36.4	12.6	-30.7	-40.4	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Cue Biopharma (CUE)	-72.0	-58.4	-7.4	-74.8	-9.6	-21.2	237.8
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Cue Biopharma (CUE)	27.9	202.5	37.7	-164.1	-260.6	-1141.9	--	88.6
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Cue Biopharma (CUE)

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2... development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Read more

CEO & Director

Mr. Daniel R. Passeri J.D., M.Sc.
CEO & Director

Mr. Daniel R. Passeri J.D., M.Sc.
Headquarters

Boston, MA
Website

https://www.cuebiopharma.com

FAQs for Cue Biopharma (CUE)

What is the current share price of Cue Biopharma (CUE) Today?

The share price of Cue Biopharma (CUE) is $27.88 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Cue Biopharma (CUE) has given a return of -30.68% in the last 3 years.

What is the current PB & PE ratio of Cue Biopharma (CUE)?

Since, TTM earnings of Cue Biopharma (CUE) is negative, P/E ratio is not available.
The P/B ratio of Cue Biopharma (CUE) is 88.56 times as on 28-Aug-2026, a 1555 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.